138227-63-1

Basic information

• Product Name: 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE
• Synonyms: 4-(4-AMINO-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1N-BOC 4-(4'-AMINOPHENOXY) PIPERIDINE;1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE;Boc-4-(4-amino-phenoxy)piperidine;tert-Butyl 4-(4-aminophenoxy)-1-piperidinecarboxylate;tert-Butyl 4-(4-aminophenoxy)tetrahydro-1(2H)-pyridinecarboxylate;4-{[1-(tert-Butoxycarbonyl)piperidin-4-yl]oxy}aniline;tert-Butyl 4-(4-aminophenoxy)piperidine-1-carboxylate
• CAS NO: 138227-63-1
• Molecular Formula: C₁₆H₂₄N₂O₃
• Molecular Weight: 292.37
• Product Categories: pharmacetical
• Mol File: 138227-63-1.mol

Chemical Properties

• Boiling Point: 430.312 °C at 760 mmHg
• Flash Point: 214.045 °C
• Appearance: /
• Density: 1.14 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE(138227-63-1)
• EPA Substance Registry System: 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE(138227-63-1)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 138227-63-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE is used as a synthetic intermediate for the development of new pharmaceuticals, leveraging its unique structural features to create molecules with specific biological activities. The BOC protecting group allows for the synthesis of complex molecules with controlled reactivity, while the amino-phenoxy group may contribute to the compound's interaction with biological targets.
Used in Chemical Research:
In the field of chemical research, 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE is used as a key component in the synthesis of various organic compounds. Its structural elements enable the exploration of new chemical reactions and the creation of novel materials with tailored properties.
Used in Drug Development:
1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE is utilized as a precursor in drug development, where its specific chemical and biological properties can be harnessed to design and optimize therapeutic agents. 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE's versatility allows for the generation of a wide range of drug candidates with potential applications in various therapeutic areas.
Used in Material Science:
In material science, 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE is employed as a building block for the creation of new materials with specialized properties. 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE's structural elements can be integrated into polymers, coatings, or other materials to impart unique characteristics, such as improved stability, reactivity, or biological compatibility.
Overall, 1-BOC-4-(4-AMINO-PHENOXY)-PIPERIDINE is a valuable compound in multiple scientific disciplines, offering a foundation for innovation in pharmaceuticals, chemistry, drug development, and material science. Its unique structural features and potential applications make it an important tool for researchers in these fields.

InChI:InChI=1/C16H24N2O3/c1-16(2,3)21-15(19)18-10-8-14(9-11-18)20-13-6-4-12(17)5-7-13/h4-7,14H,8-11,17H2,1-3H3

Upstream product

• 123-30-8 4-amino-phenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 138227-62-0 tert-butyl 4-(4-nitrophenoxy)piperidine-1-carboxylate 
• 100-02-7 4-nitro-phenol 
• 141-78-6 ethyl acetate 
• 350-46-9 4-Fluoronitrobenzene 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 179755-93-2 7-({4-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-anilino}methyl)naphthalene-2-carbonitrile 
• 454437-33-3 N-{4-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]phenyl}methanesulfonamide 
• 337519-98-9 3-((E)-3-{4-[1-(t-butoxycarbonyl)piperidin-4-yloxy]phenylamino}-1-propenyl)benzonitrile 
• 484065-66-9 N-{4-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]phenyl}ethenesulfonamide 
• 179756-35-5 N-{4-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]phenyl}-7-cyano-2-naphthamide 
• 221161-00-8 4-{4-[(5-cyano-benzofuran-2-carbonyl)-amino]-phenoxy}-piperidine-1-carboxylic acid tert-butyl ester 
• 247132-55-4 4-(4-Benzyloxycarbonylaminophenoxy)piperidine-1-carboxylic Acid tert-Butyl ester 
• 247132-57-6 N-[4-(1-tert-butoxycarbonylpiperidin-4-yloxy)phenyl]-N-benzyloxycarbonyl-aminoacetic acid 
• 247132-56-5 4-[4-(N-benzyloxycarbonyl-N-ethoxycarbonyl-methylamino)phenoxy]piperidine-1-carboxylic acid tert-butyl ester 
• 247133-78-4 2-[4-(1-tert-Butoxycarbonylpiperidin-4-yloxy)phenylaminomethyl]-1-(cyclohexylcarbamoylmethyl)-5-cyanobenzimdazole 
• 247132-61-2 2-[N-Benzyloxycarbonyl-N-[4-(1-tert-butoxycarbonylpiperidin-4-yloxy)phenyl]-aminomethyl]-5-cyanobenzimidazole-1-acetic Acid 

Relevant articles and documents

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER

The invention provides compounds of the formula (1): or a salt or tautomer thereof wherein A, R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are inhibitors of Wee1 and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers.

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.

Catalytic Selective Oxidative Coupling of Secondary N-Alkylanilines: An Approach to Azoxyarene

Azoxyarenes are among important scaffolds in organic molecules. Direct oxidative coupling of primary anilines provides a concise fashion to construct them. However, whether these scaffolds can be prepared from secondary N-alkylanilines is not well explored. Here, we present a catalytic selective oxidative coupling of secondary N-alkylaniline to afford azoxyarene with tungsten catalyst under mild conditions. In addition, azoxy can be viewed as a bioisostere of alkene and amide. Several "azoxyarene analogues" of the corresponding bioactive alkenes and amides showed comparable promising anticancer activities.

SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I), wherein R1, R2a, R,2b,Z

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, de? formations and chromosomal abnormalities.

Straightforward synthesis of a novel ring-fused pyrazole-lactam and in vitro cytotoxic activity on cancer cell lines

In this paper a straightforward synthesis of a novel pyrazole derivative is reported. Prominent feature of this synthetic process is a 1,3-Dipolar Cycloaddition of a suitable nitrile imine with an activated α,β-unsaturated lactam to afford directly and re

PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS

The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

VEGFR3 INHIBITORS

This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Cinnamyl derivatives: Synthesis and factor Xa (FXa) inhibitory activities

To develop a potent and oral anticoagulant, a series of compounds with cinnamyl moiety was synthesized and their factor Xa (FXa) inhibitory activities were examined. As a result, some cinnamyl derivatives showed potent FXa inhibitory activities in vitro. Among them, compounds with substituent at the 3-position on the central benzene ring represented by (N-{4-[1-(acetimidoyl) piperidin-4-yloxy]-3-chlorophenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl] sulfamoyl)acetic acid dihydrochloride (45b) and (N-{4-[1-(acetimidoyl)piperidin- 4-yloxy]-3-carbamoylphenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl]sulfamoyl) acetic acid dihydrochloride (45j) exhibited potent FXa inhibitory activities with IC50 values of less than 10 nM in vitro. These compounds also showed potent anticoagulant activities both in vitro and ex vivo. Furthermore, these compounds exhibited no lethal toxicity (30 mg/kg, i.v.).